AlzeCure gets abstract accepted on new potential disease-modifying effects of ACD856 against Alzheimer's

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that an abstract with new preclinical data supporting a disease-modifying effect of ACD856 has been accepted for presentation at the Alzheimer's Conference AD/PD 2023, to be held in Gothenburg, Sweden, March 28 - April 1.

The abstract, titled Effects on neuroprotection and neuroplasticity by the clinical compound ACD856, a novel positive modulator of Trk-receptors from the NeuroRestore® platform, will be presented by Johan Sandin, CSO at AlzeCure, at the international conference on Alzheimer's, Parkinson's disease and related neurological diseases (AD/PD 2023). Other authors are Sanja Juric, Cristina Parrado-Fernández, Nather Madjid, Gunnar Nordvall, Maria Backlund, Märta Dahlström and Pontus Forsell.

The presentation contains new preclinical results with ACD856, the leading drug candidate in the NeuroRestore platform, which in the studies shows, among other things, a protective effect on nerve cells and a positive effect of ACD856 on the growth of nerve fibers. Furthermore, the data show that ACD856 increases the amount of a specific protein that plays an important role in nerve cell communication, something that is strongly affected in the disease.

A positive modulator of both NGF/TrkA- and BDNF/TrkB-mediated signaling, ACD856 has been shown in preclinical studies to improve cognition and memory. In subsequent clinical studies, the substance has shown good tolerability and safety, central target engagement and is being developed primarily for the treatment of Alzheimer's disease.

“These new positive data build on the previous findings we made with our substances in the NeuroRestore platform and further strengthen and validate their potential for disease-modifying effects,” said Pontus Forsell, Head of Discovery & Research at AlzeCure.

"We have previously shown that ACD856 has potent learning and memory-enhancing effects in preclinical models and that we now, in addition, are able to demonstrate disease-modifying properties is something that can significantly increase commercial interest in the substance, which is now ready for phase 2 clinical studies," said Martin Jönsson, CEO of AlzeCure Pharma.

The abstract and poster will be available on AlzeCure's website after the presentation (https://www.alzecurepharma.se/en/presentations-and-interviews/).